Consumption of fat-soluble statin reduces the risk of developing Parkinson’s disease

Millions people consume statins to diminish their stroke and heart attack dangers, but new research proposes that the drug may tender another health benefit: curbing the odds of developing Parkinson’s disease. Examining nearly 44,000 patients, the researchers discovered that those who stopped consuming fat-soluble statins such as atorvastatin or simvastatin were about 58 percent more likely to evolve Parkinson’s than those who kept taking the drugs.

Fat-soluble statins are believed to cross the blood-brain barrier, disparate water-soluble statins such as rosuvastatin (Crestor) and pravastatin (Pravachol). The drugs may decrease inflammation and even alter dopamine pathways in the brain, which are associated to Parkinson’s.

The drugs are used to reduce cholesterol levels in the liver. The researchers evaluated the potential difference in Parkinson’s risk in people who stopped statin use compared to those who continued taking the drug. Parkinson’s disease is an advanced neurological situation resulting in movement problems such as tremors, stiffness, and slurred speech.

Prior research examining the link between statin use and Parkinson’s disease showed inconsistent results. The new study showed that participants taking water-soluble statins developed Parkinson’s at about twice the rate as those taking fat-soluble statins. According to the findings the researchers also added that those at risk for developing Parkinson’s may elect to take a [fat-soluble] statin for the potential hope of delaying the appearance of Parkinson’s disease symptoms. Family history of Parkinson’s is contemplated to increase the danger for the disorder.

Additionally, if you’re on one of these types of statin drugs, it may be advisable not to stop it. People who already have the diagnosis of Parkinson’s disease should be aware that there is no proven benefit to starting one of these drugs after diagnosis.

For more please visit :

100 Railway Street,
Sydney, NSW,

Andy decosta completed his graduation in Biotechnology and also did PhD in Bio-pharmacology. He works as a medical consultant for

Be Sociable, Share!